Literature DB >> 32402525

Hepatic fibrosis: A convergent response to liver injury that is reversible.

Shuang Wang1, Scott L Friedman2.   

Abstract

Entities:  

Keywords:  Apoptosis; Deactivation; Fibrosis; Inflammation; Injury; Liver; Liver sinusoidal endothelial cells; Stellate cells

Year:  2020        PMID： 32402525     DOI： 10.1016/j.jhep.2020.03.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  13 in total

Review 1.  Fibrosis regression following hepatitis C antiviral therapy.

Authors:  Aisha Elsharkawy; Reham Samir; Mohamed El-Kassas
Journal:  World J Hepatol       Date:  2022-06-27

Review 2.  Potential Therapeutic Targets and Promising Agents for Combating NAFLD.

Authors:  Atsushi Umemura; Seita Kataoka; Keiichiro Okuda; Yuya Seko; Kanji Yamaguchi; Michihisa Moriguchi; Takeshi Okanoue; Yoshito Itoh
Journal:  Biomedicines       Date:  2022-04-14

Review 3.  Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis.

Authors:  Dmitry Victorovich Garbuzenko
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

Review 4.  The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells.

Authors:  Parth Trivedi; Shuang Wang; Scott L Friedman
Journal:  Cell Metab       Date:  2020-11-23       Impact factor: 27.287

Review 5.  Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.

Authors:  Don C Rockey; Scott L Friedman
Journal:  Gastroenterology       Date:  2021-01-30       Impact factor: 22.682

6.  Cytoplasmic vacuolation with endoplasmic reticulum stress directs sorafenib induced non-apoptotic cell death in hepatic stellate cells.

Authors:  Sachin Sharma; Shaikh Maryam Ghufran; Sampa Ghose; Subhrajit Biswas
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

7.  Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis.

Authors:  Hiroyuki Ogawa; Kosuke Kaji; Norihisa Nishimura; Hirotetsu Takagi; Koji Ishida; Hiroaki Takaya; Hideto Kawaratani; Kei Moriya; Tadashi Namisaki; Takemi Akahane; Hitoshi Yoshiji
Journal:  J Cell Mol Med       Date:  2021-02-20       Impact factor: 5.310

8.  Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.

Authors:  Arun J Sanyal; Lei Ling; Ulrich Beuers; Alex M DePaoli; Hsiao D Lieu; Stephen A Harrison; Gideon M Hirschfield
Journal:  JHEP Rep       Date:  2021-02-19

Review 9.  Hyperpolarized carbon 13 MRI in liver diseases: Recent advances and future opportunities.

Authors:  Zheng Ye; Bin Song; Philip M Lee; Michael A Ohliger; Christoffer Laustsen
Journal:  Liver Int       Date:  2022-03-12       Impact factor: 8.754

Review 10.  Metabolic Reprogramming of Liver Fibrosis.

Authors:  M Eugenia Delgado; Beatriz I Cárdenas; Núria Farran; Mercedes Fernandez
Journal:  Cells       Date:  2021-12-20       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.